Please assess the completion status of the following clinical trial:

Trial Title: Preimplantation Genetic Diagnosis (PGD) by Array Comparative Genome Hybridization (CGH) and Blastocyst Biopsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Couples with women 30-42 years of age~* Follicle Stimulating Hormone (FSH) level \<11IU/L on day 3 of cycle.~Exclusion Criteria:~* TESA and TESE patients~* Couples' carriers of chromosomal or genetic diseases~* Couples that produce less than eight antral follicles on day 2-4 of cycle~* Patients will be excluded if they produce no blastocysts by day 5

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 42 Years
- Healthy Volunteers: f

Study Arms:
- Test (Type: ACTIVE_COMPARATOR): The test group will consist of patients undergoing blastocyst biopsy followed by vitrification (embryo freezing), and in which the biopsied cells will be analyzed with a comprehensive chromosome analysis technique (array Comparative Genome hybridization or aCGH) and only one chromosomally normal embryo will be replaced in a thawed cycle.
- control (Type: NO_INTERVENTION): The control group will consist of patients in which one embryo will be replaced on day 5 based on morphological and developmental characteristics, and the other embryos reaching blastocyst stage will be vitrified. If patient does not become pregnant, successive embryo transfers of frozen embryos will be performed, but not as part of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).